Chemotherapy, Biologic, and Immunotherapy Breakthroughs in Cancer Care

Christine Rojas; Yovanni Casablanca

doi:10.1016/j.ogc.2018.09.009

Chemotherapy, Biologic, and Immunotherapy Breakthroughs in Cancer Care

Christine Rojas, Yovanni Casablanca^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

As the understanding of cancer biology expands, a wider array of treatment options has become available in the field of gynecologic cancer. Therapies that target specific molecular pathways are now being used. Drugs that target cancer angiogenesis, signal transduction, DNA repair, and immune evasion mechanisms are currently being used, in addition to or in lieu of traditional chemotherapy, to achieve more personalized treatment of each patient and their unique disease. These therapies may lead to improved survival outcomes and quality of life during treatment and during remission.

Original language	English
Pages (from-to)	137-154
Number of pages	18
Journal	Obstetrics and Gynecology Clinics of North America
Volume	46
Issue number	1
DOIs	https://doi.org/10.1016/j.ogc.2018.09.009
State	Published - Mar 2019
Externally published	Yes

Keywords

Antiangiogenic therapy
Chemotherapy
Immunotherapy
PARP inhibitors
Targeted therapy
Toxicity
Tyrosine kinase inhibitors (TKI)

Access to Document

10.1016/j.ogc.2018.09.009

Cite this

@article{fcb2530dea2c475a8316bb7edf912139,

title = "Chemotherapy, Biologic, and Immunotherapy Breakthroughs in Cancer Care",

abstract = "As the understanding of cancer biology expands, a wider array of treatment options has become available in the field of gynecologic cancer. Therapies that target specific molecular pathways are now being used. Drugs that target cancer angiogenesis, signal transduction, DNA repair, and immune evasion mechanisms are currently being used, in addition to or in lieu of traditional chemotherapy, to achieve more personalized treatment of each patient and their unique disease. These therapies may lead to improved survival outcomes and quality of life during treatment and during remission.",

keywords = "Antiangiogenic therapy, Chemotherapy, Immunotherapy, PARP inhibitors, Targeted therapy, Toxicity, Tyrosine kinase inhibitors (TKI)",

author = "Christine Rojas and Yovanni Casablanca",

note = "Publisher Copyright: {\textcopyright} 2018",

year = "2019",

month = mar,

doi = "10.1016/j.ogc.2018.09.009",

language = "English",

volume = "46",

pages = "137--154",

journal = "Obstetrics and Gynecology Clinics of North America",

issn = "0889-8545",

number = "1",

}

TY - JOUR

T1 - Chemotherapy, Biologic, and Immunotherapy Breakthroughs in Cancer Care

AU - Rojas, Christine

AU - Casablanca, Yovanni

PY - 2019/3

Y1 - 2019/3

N2 - As the understanding of cancer biology expands, a wider array of treatment options has become available in the field of gynecologic cancer. Therapies that target specific molecular pathways are now being used. Drugs that target cancer angiogenesis, signal transduction, DNA repair, and immune evasion mechanisms are currently being used, in addition to or in lieu of traditional chemotherapy, to achieve more personalized treatment of each patient and their unique disease. These therapies may lead to improved survival outcomes and quality of life during treatment and during remission.

AB - As the understanding of cancer biology expands, a wider array of treatment options has become available in the field of gynecologic cancer. Therapies that target specific molecular pathways are now being used. Drugs that target cancer angiogenesis, signal transduction, DNA repair, and immune evasion mechanisms are currently being used, in addition to or in lieu of traditional chemotherapy, to achieve more personalized treatment of each patient and their unique disease. These therapies may lead to improved survival outcomes and quality of life during treatment and during remission.

KW - Antiangiogenic therapy

KW - Chemotherapy

KW - Immunotherapy

KW - PARP inhibitors

KW - Targeted therapy

KW - Toxicity

KW - Tyrosine kinase inhibitors (TKI)

UR - http://www.scopus.com/inward/record.url?scp=85060304326&partnerID=8YFLogxK

U2 - 10.1016/j.ogc.2018.09.009

DO - 10.1016/j.ogc.2018.09.009

M3 - Review article

C2 - 30683260

AN - SCOPUS:85060304326

SN - 0889-8545

VL - 46

SP - 137

EP - 154

JO - Obstetrics and Gynecology Clinics of North America

JF - Obstetrics and Gynecology Clinics of North America

IS - 1

ER -

Chemotherapy, Biologic, and Immunotherapy Breakthroughs in Cancer Care

Abstract

Keywords

Access to Document

Fingerprint

Cite this